Dr.NateNeph said:The gap between trial results and real-world results is consistent and it is not fraud.
Bookmarking. The distinction being drawn above is the one nobody else makes.
Clinical perspective, offered as context rather than as advice.
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:
The the trial evidence meta-analysis shows a pooled RR of 0.82 (95% CI 0.65-0.82), I²=40%. This is a robust and consistent effect.
hans_munich said:Relative and absolute effects need reading together.
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.
For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."
The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsTrialTracker_MD said:ClinicalTrials.gov GLP-1 trial tracker — updated weekly Posting this as an important update for the clinical trials & research community.
TrialTracker_MD said:...regarding the trial evidence...
I think this is an underappreciated point. To expand on it with some data:
A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].
The NNT was 8, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.